Metastatic Colorectal Cancers Completed Phase 2 Trials for Oxaliplatin (DB00526)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

DBCOND0063579 (Metastatic Colorectal Cancers)Completed2 IdentifierTitlePurposeDrugs
NCT01163396First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerTreatment
NCT01321957Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal CancerTreatment
NCT00803647A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the LiverTreatment
NCT00205322Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal CancerTreatment
NCT00254137Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.Treatment
NCT00286130Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal CancerTreatment
NCT003456961stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.Treatment
NCT00378066Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon CancerTreatment
NCT00689624Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal CancerTreatment
NCT00835185Study of IMC-11F8 in Participants With Colorectal CancerTreatment
NCT00865709Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) SubjectsTreatment
NCT01022541Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal CancerTreatment
NCT01024504Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal CancerTreatment
NCT01225744Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted TherapyTreatment
NCT01399684A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal CancerTreatment